Notice is hereby given that TD Origen Fund, L.P. (“TD Origen”), 150 Washington Avenue, Suite 201, Santa Fe, New Mexico 87501, a Federal Licensee under the Small Business Investment Act of 1958, as amended (“the Act”), TD Javelin Capital Fund, LP (“TD Javelin I”), 2850 Cahaba Road, Suite 240, Birmingham, Alabama 35223, a Federal Licensee under the Act, and TD Javelin Capital Fund II, LP (“TD Javelin II”), 2850 Cahaba Road, Suite 240, Birmingham, Alabama 35223 (collectively “the Funds”), in connection with the financing of a small concern, have sought an exemption under section 312 of the Act and section 107.730, Financings which Constitute Conflicts of Interest of the Small Business Administration (“SBA”) rules and regulations (13 CFR 107.730 (2000)). The Funds propose to provide equity financing to Phase-1 Molecular Toxicology, Inc. (“Phase-1”), 2904 Rodeo Park Drive East, Santa Fe, New Mexico 97505. The financing is contemplated for product development and working capital.
The financing is brought within the purview of Sec. 107.730(a)(1) of the Start Printed Page 26869Regulations because TD Origen and TD Javelin, Associates of the Funds, currently own greater than 10 percent of Phase-1 and therefore Phase-1 is considered an Associate of each of the Funds as defined in Sec. 107.50 of the regulations.
Notice is hereby given that any interested person may submit written comments on the transaction to the Associate Administrator for Investment, U.S. Small Business Administration, 409 Third Street, SW, Washington, DC 20416.Start Signature
Dated: April 26, 2000.
Don A. Christensen,
Associate Administrator for Investment.
[FR Doc. 00-11497 Filed 5-8-00; 8:45 am]
BILLING CODE 8025-01-P